Yuxin Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuxin Liu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Keith Sigel
Department of Medicine, Division of General Internal Medicine
8 shared publications- Keith Sigel
Icahn School of Medicine at Mount Sinai, New York, NY
4 shared publications Michael M Gaisa
Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York , USA
4 shared publicationsMichael M. Gaisa
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai
4 shared publicationsTamara Kalir
Division of Gynecologic Pathology, Department of Pathology, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, NY 10029
4 shared publicationsWenxin Zheng
Department of Pathology, Obstetrics and Gynecology, Simon Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
4 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (12) , 1470-1478
Folate Receptor Alpha Expression Across the Spectrum of Serous Tubal Lesions
Folate receptor alpha (FRα) is highly expressed in tubo-ovarian high-grade serous carcinoma (HGSC), but its expression in serous tubal intraepithelial carcinoma (STIC) and earlier tubal lesions has not been systematically characterized. We evaluated FRα expression across the spectrum of fallopian tube lesions and assessed its potential as an adjunctive diagnostic biomarker. Immunohistochemistry was performed on 408 tubal epithelial samples from 262 patients, including 52 normal fallopian tube samples, 110 secretory cell expansions (SCE), 88 secretory cell outgrowths (SCOUT), 72 serous tubal intraepithelial lesions (STIL), and 56 STICs. An additional 30 HGSCs were included for comparison. FRα expression was assessed using the percentage score ≥2+ (PS2+) system. Associations with germline BRCA status and age were evaluated. FRα expression was detectable in normal fallopian tube epithelium but usually below the high-expression threshold. In contrast, expression was increased in STIC and HGSC, with high PS2+ scores in 73.2% and 76.7% of cases, respectively. Earlier tubal lesions showed predominantly low or negative/very low expression. No significant difference in FRα expression was observed between STIC and HGSC. BRCA-mutated STIC and HGSC showed higher FRα expression than their BRCA nonmutated counterparts, whereas earlier lesions showed no such association. In normal fallopian tube epithelium, FRα expression decreased with age. These findings demonstrate that FRα upregulation is established at the STIC stage and maintained in invasive HGSC. Diffuse high-level expression is uncommon in STIL and earlier lesions, suggesting that FRα may serve as an adjunct biomarker for distinguishing STIC from morphologically overlapping lesions. When interpreted in conjunction with morphology, p53, and Ki-67, FRα may improve diagnostic confidence along the STIL-to-STIC spectrum. The early and sustained upregulation of FRα in STIC also raises interesting questions regarding the timing of FRα-targeted interventions.
- 1 September 2026
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 50 (12) , 1470-1478
Folate Receptor Alpha Expression Across the Spectrum of Serous Tubal Lesions
Folate receptor alpha (FRα) is highly expressed in tubo-ovarian high-grade serous carcinoma (HGSC), but its expression in serous tubal intraepithelial carcinoma (STIC) and earlier tubal lesions has not been systematically characterized. We evaluated FRα expression across the spectrum of fallopian tube lesions and assessed its potential as an adjunctive diagnostic biomarker. Immunohistochemistry was performed on 408 tubal epithelial samples from 262 patients, including 52 normal fallopian tube samples, 110 secretory cell expansions (SCE), 88 secretory cell outgrowths (SCOUT), 72 serous tubal intraepithelial lesions (STIL), and 56 STICs. An additional 30 HGSCs were included for comparison. FRα expression was assessed using the percentage score ≥2+ (PS2+) system. Associations with germline BRCA status and age were evaluated. FRα expression was detectable in normal fallopian tube epithelium but usually below the high-expression threshold. In contrast, expression was increased in STIC and HGSC, with high PS2+ scores in 73.2% and 76.7% of cases, respectively. Earlier tubal lesions showed predominantly low or negative/very low expression. No significant difference in FRα expression was observed between STIC and HGSC. BRCA-mutated STIC and HGSC showed higher FRα expression than their BRCA nonmutated counterparts, whereas earlier lesions showed no such association. In normal fallopian tube epithelium, FRα expression decreased with age. These findings demonstrate that FRα upregulation is established at the STIC stage and maintained in invasive HGSC. Diffuse high-level expression is uncommon in STIL and earlier lesions, suggesting that FRα may serve as an adjunct biomarker for distinguishing STIC from morphologically overlapping lesions. When interpreted in conjunction with morphology, p53, and Ki-67, FRα may improve diagnostic confidence along the STIL-to-STIC spectrum. The early and sustained upregulation of FRα in STIC also raises interesting questions regarding the timing of FRα-targeted interventions.
- Open Access
- 19 December 2025
- Published by Xia & He Publishing in Journal of Clinical and Translational Pathology
- Vol. 5 (4) , 143-147
A Clinicopathologic Analysis of 740 Endometrial Polyps: Risk of Premalignant Changes and Malignancy
Endometrial polyp (EMP) is one of the most common diagnoses in the evaluation of women with abnormal uterine bleeding. Understanding the malignancy risk associated with EMPs and related risk factors is essential for guiding both pathology practice and clinical management. This study aimed to explore risk factors for malignancy in EMPs.
- 19 December 2025
- Published by Xia & He Publishing in Journal of Clinical and Translational Pathology
- Vol. 5 (4) , 143-147
Open AccessA Clinicopathologic Analysis of 740 Endometrial Polyps: Risk of Premalignant Changes and Malignancy
Endometrial polyp (EMP) is one of the most common diagnoses in the evaluation of women with abnormal uterine bleeding. Understanding the malignancy risk associated with EMPs and related risk factors is essential for guiding both pathology practice and clinical management. This study aimed to explore risk factors for malignancy in EMPs.
- 10 June 2025
- Published by Springer Nature
- p. 493-508
Cervical Cancer Development, Screening, and Prevention
- 10 June 2025
- Published by Springer Nature
- p. 493-508
Cervical Cancer Development, Screening, and Prevention
- 12 March 2025
- Published by Wiley in International Journal of Cancer
- Vol. 156 (12) , 2455-2457
Reply to comments on: “International Anal Neoplasia Society's consensus guidelines for anal cancer screening”
- 12 March 2025
- Published by Wiley in International Journal of Cancer
- Vol. 156 (12) , 2455-2457
Reply to comments on: “International Anal Neoplasia Society's consensus guidelines for anal cancer screening”
- 3 February 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (2) , 345-347
2024 Anal Cancer Screening Guidelines: Analysis of Clinical Performance and Use of High-Resolution Anoscopy in a Large Cohort of Persons With HIV
Recently published anal cancer screening guidelines recommend 5 strategies for high-risk populations using combinations of cytology and high-risk human papillomavirus testing. Based on data from 1223 persons with human immunodeficiency virus, all triage and cotesting strategies outperformed cytology alone. High-risk human papillomavirus testing improved specificity and reduced high-resolution anoscopy referrals, essential for guideline implementation.
- 3 February 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (2) , 345-347
2024 Anal Cancer Screening Guidelines: Analysis of Clinical Performance and Use of High-Resolution Anoscopy in a Large Cohort of Persons With HIV
Recently published anal cancer screening guidelines recommend 5 strategies for high-risk populations using combinations of cytology and high-risk human papillomavirus testing. Based on data from 1223 persons with human immunodeficiency virus, all triage and cotesting strategies outperformed cytology alone. High-risk human papillomavirus testing improved specificity and reduced high-resolution anoscopy referrals, essential for guideline implementation.
- 25 April 2024
- Published by Springer Nature
- p. 1-16
Cervical Cancer Development, Screening, and Prevention
- 25 April 2024
- Published by Springer Nature
- p. 1-16
Cervical Cancer Development, Screening, and Prevention
- Top Cited PapersOpen Access
- 31 January 2024
- Published by Wiley in International Journal of Cancer
- Vol. 154 (10) , 1694-1702
International Anal Neoplasia Society's consensus guidelines for anal cancer screening
The International Anal Neoplasia Society (IANS) developed consensus guidelines to inform anal cancer screening use among various high‐risk groups. Anal cancer incidence estimates by age among risk groups provided the basis to identify risk thresholds to recommend screening. Guided by risk thresholds, screening initiation at age 35 years was recommended for men who have sex with men (MSM) and transgender women (TW) with HIV. For other people with HIV and MSM and TW not with HIV, screening initiation at age 45 years was recommended. For solid organ transplant recipients, screening initiation beginning from 10 years post‐transplant was recommended. For persons with a history of vulvar precancer or cancer, screening initiation was recommended starting within 1 year of diagnosis of vulvar precancer or cancer. Persons aged ≥45 years with a history of cervical/vaginal HSIL or cancer, perianal warts, persistent (>1 year) cervical HPV16, or autoimmune conditions could be considered for screening with shared decision‐making, provided there is adequate capacity to perform diagnostic procedures (high‐resolution anoscopy [HRA]). Anal cytology, high‐risk (hr) human papillomavirus (HPV) testing (including genotyping for HPV16), and hrHPV‐cytology co‐testing are different strategies currently used for anal cancer screening that show acceptable performance. Thresholds for referral for HRA or follow‐up screening tests are delineated. These recommendations from IANS provide the basis to inform management of abnormal screening results, considering currently available screening tools. These guidelines provide a pivotal foundation to help generate consensus among providers and inform the introduction and implementation of risk‐targeted screening for anal cancer prevention.
- 31 January 2024
- Published by Wiley in International Journal of Cancer
- Vol. 154 (10) , 1694-1702
Top Cited PapersOpen AccessInternational Anal Neoplasia Society's consensus guidelines for anal cancer screening
The International Anal Neoplasia Society (IANS) developed consensus guidelines to inform anal cancer screening use among various high‐risk groups. Anal cancer incidence estimates by age among risk groups provided the basis to identify risk thresholds to recommend screening. Guided by risk thresholds, screening initiation at age 35 years was recommended for men who have sex with men (MSM) and transgender women (TW) with HIV. For other people with HIV and MSM and TW not with HIV, screening initiation at age 45 years was recommended. For solid organ transplant recipients, screening initiation beginning from 10 years post‐transplant was recommended. For persons with a history of vulvar precancer or cancer, screening initiation was recommended starting within 1 year of diagnosis of vulvar precancer or cancer. Persons aged ≥45 years with a history of cervical/vaginal HSIL or cancer, perianal warts, persistent (>1 year) cervical HPV16, or autoimmune conditions could be considered for screening with shared decision‐making, provided there is adequate capacity to perform diagnostic procedures (high‐resolution anoscopy [HRA]). Anal cytology, high‐risk (hr) human papillomavirus (HPV) testing (including genotyping for HPV16), and hrHPV‐cytology co‐testing are different strategies currently used for anal cancer screening that show acceptable performance. Thresholds for referral for HRA or follow‐up screening tests are delineated. These recommendations from IANS provide the basis to inform management of abnormal screening results, considering currently available screening tools. These guidelines provide a pivotal foundation to help generate consensus among providers and inform the introduction and implementation of risk‐targeted screening for anal cancer prevention.
- 20 September 2023
- Published by Wiley in International Journal of Cancer
- Vol. 154 (1) , 21-27
Anal cancer screening results from 18‐to‐34‐year‐old men who have sex with men living with HIV
Men who have sex with men living with HIV (MSM LWH) are at highest risk for human papillomavirus (HPV)‐associated anal cancer. There is no consensus on the optimal screening initiation age. This study aimed to assess the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, which is a currently proposed screening age threshold. Between 2014 and 2020, 1255 18‐to‐34‐year‐old MSM LWH underwent anal cytology screening. 916 were co‐tested for high‐risk HPV (HR‐HPV). 467 underwent high‐resolution anoscopy (HRA) and biopsy. Cancer registry data were queried. Predictors of abnormal cytology (ie, ≥ASCUS) and histological high‐grade squamous intraepithelial lesions (HSIL) were evaluated using unadjusted logistic regression models. Median age was 28 years (range, 18‐34). 19% received at least one dose of HPV vaccine. Abnormal cytology rate was 65%. HR‐HPV and HPV16 prevalence were 87% and 30%. Biopsy results were benign (10%), LSIL (43%) and HSIL (47%). No cases of prevalent or incident anal cancers were detected. Findings were similar between age subgroups (18‐24, 25‐29 and 30‐34) except for a higher prevalence of AIN 3 in the 30‐34 group (19%). Abnormal cytology was significantly associated with HR‐HPV infection. Histological HSIL was associated with HR‐HPV infection and cytological LSIL or worse. The absence of anal cancer in a large cohort of MSM LWH under the age of 35, despite high prevalence of anal HR‐HPV infection and precancer, supports an age‐based anal cancer screening strategy for MSM LWH.
- 20 September 2023
- Published by Wiley in International Journal of Cancer
- Vol. 154 (1) , 21-27
Anal cancer screening results from 18‐to‐34‐year‐old men who have sex with men living with HIV
Men who have sex with men living with HIV (MSM LWH) are at highest risk for human papillomavirus (HPV)‐associated anal cancer. There is no consensus on the optimal screening initiation age. This study aimed to assess the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, which is a currently proposed screening age threshold. Between 2014 and 2020, 1255 18‐to‐34‐year‐old MSM LWH underwent anal cytology screening. 916 were co‐tested for high‐risk HPV (HR‐HPV). 467 underwent high‐resolution anoscopy (HRA) and biopsy. Cancer registry data were queried. Predictors of abnormal cytology (ie, ≥ASCUS) and histological high‐grade squamous intraepithelial lesions (HSIL) were evaluated using unadjusted logistic regression models. Median age was 28 years (range, 18‐34). 19% received at least one dose of HPV vaccine. Abnormal cytology rate was 65%. HR‐HPV and HPV16 prevalence were 87% and 30%. Biopsy results were benign (10%), LSIL (43%) and HSIL (47%). No cases of prevalent or incident anal cancers were detected. Findings were similar between age subgroups (18‐24, 25‐29 and 30‐34) except for a higher prevalence of AIN 3 in the 30‐34 group (19%). Abnormal cytology was significantly associated with HR‐HPV infection. Histological HSIL was associated with HR‐HPV infection and cytological LSIL or worse. The absence of anal cancer in a large cohort of MSM LWH under the age of 35, despite high prevalence of anal HR‐HPV infection and precancer, supports an age‐based anal cancer screening strategy for MSM LWH.
- 5 October 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 227 (8) , 932-938
Primary Anal Cancer Screening Results From 381 Women With Human Immunodeficiency Virus
Background: Women with human immunodeficiency virus (WWH) have an elevated risk for human papillomavirus (HPV)-associated anal cancer. Primary anal cancer screening results from this population could inform practice guidelines. Methods: In total, 381 WWH with anal cytology screening, high-risk HPV (hrHPV) testing and genital (cervical or vaginal) cotesting within 6 months were identified during 2012–2019. Those with anal cytology of atypical squamous cells of undetermined significance (ASCUS) or worse underwent high-resolution anoscopy and biopsy. Independent predictors of anal hrHPV, HPV16, and histological anal high-grade squamous intraepithelial lesions (aHSIL) were identified using adjusted logistic regression models. Results: Prevalence of anal hrHPV, HPV16, and ASCUS or worse cytology was 61%, 13%, and 68%. Histological aHSIL was detected in 42% of WWH with ASCUS or worse anal cytology. Prevalence of genital hrHPV, HPV16, and ASCUS or worse cytology was 30%, 4%, and 28%. Genital hrHPV predicted anal hrHPV (odds ratio [OR], 5.05), while genital HPV16 predicted anal HPV16 (OR, 9.52). Genital hrHPV and anal HPV16 predicted histological aHSIL (ORs, 2.78 and 10.9). Conclusions: Anal HPV disease was highly prevalent in this primary screening cohort of WWH. While genital screening results predicted anal disease, rates of isolated anal HPV disease were substantial, supporting universal anal cancer screening for this population.
- 5 October 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 227 (8) , 932-938
Primary Anal Cancer Screening Results From 381 Women With Human Immunodeficiency Virus
Background: Women with human immunodeficiency virus (WWH) have an elevated risk for human papillomavirus (HPV)-associated anal cancer. Primary anal cancer screening results from this population could inform practice guidelines. Methods: In total, 381 WWH with anal cytology screening, high-risk HPV (hrHPV) testing and genital (cervical or vaginal) cotesting within 6 months were identified during 2012–2019. Those with anal cytology of atypical squamous cells of undetermined significance (ASCUS) or worse underwent high-resolution anoscopy and biopsy. Independent predictors of anal hrHPV, HPV16, and histological anal high-grade squamous intraepithelial lesions (aHSIL) were identified using adjusted logistic regression models. Results: Prevalence of anal hrHPV, HPV16, and ASCUS or worse cytology was 61%, 13%, and 68%. Histological aHSIL was detected in 42% of WWH with ASCUS or worse anal cytology. Prevalence of genital hrHPV, HPV16, and ASCUS or worse cytology was 30%, 4%, and 28%. Genital hrHPV predicted anal hrHPV (odds ratio [OR], 5.05), while genital HPV16 predicted anal HPV16 (OR, 9.52). Genital hrHPV and anal HPV16 predicted histological aHSIL (ORs, 2.78 and 10.9). Conclusions: Anal HPV disease was highly prevalent in this primary screening cohort of WWH. While genital screening results predicted anal disease, rates of isolated anal HPV disease were substantial, supporting universal anal cancer screening for this population.
- 7 July 2021
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 45 (11) , 1573-1578
p16 Immunoreactivity Correlates With Morphologic Diagnosis of HPV-associated Anal Intraepithelial Neoplasia
P16 is the most useful diagnostic marker for human papillomavirus (HPV)-associated anogenital lesions. In the cervix, the pattern of p16 immunoreactivity generally correlates with lesion severity. p16 expression in anal intraepithelial neoplasia (AIN) is far less studied. Whether such correlation holds true has to be determined. We correlated the degree and pattern of p16 immunohistochemistry (IHC) results with morphologic diagnoses of 1000 anal squamous and transitional zone biopsy specimens. Using the Lower Anogenital Squamous Terminology criteria, p16 IHC results were classified as block staining, partial staining, or negative. Among 150 samples without morphologic evidence of AIN, p16 was negative in 85% and partial staining in 15%. AIN 1 (n=400) revealed diverse results: 28% negative, 35% partial, and 37% block staining. Among AIN 2 (n=298), 89% were block, 9% partial staining, and 2% negative. AIN 3 (n=152) revealed block (95%) or partial staining (5%). For the detection of AIN 2/3, p16 block staining yielded 91% sensitivity, 73% specificity, 80% positive predictive value, 91% negative predictive value, and a Youden Index of 0.64. Combining block staining and partial staining slightly increased sensitivity (99%) and negative predictive value (98%), but significantly decreased specificity (43%), positive predictive value (59%) and Youden Index (0.42, P<0.001). As with the cervix, p16 immunoreactivity correlates with morphologic diagnoses of AIN. Block staining offers the optimal diagnostic value for AIN 2/3. Caution is required since AIN 1 frequently exhibits block staining; the prognostic value of p16 warrants further investigation.
- 7 July 2021
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 45 (11) , 1573-1578
p16 Immunoreactivity Correlates With Morphologic Diagnosis of HPV-associated Anal Intraepithelial Neoplasia
P16 is the most useful diagnostic marker for human papillomavirus (HPV)-associated anogenital lesions. In the cervix, the pattern of p16 immunoreactivity generally correlates with lesion severity. p16 expression in anal intraepithelial neoplasia (AIN) is far less studied. Whether such correlation holds true has to be determined. We correlated the degree and pattern of p16 immunohistochemistry (IHC) results with morphologic diagnoses of 1000 anal squamous and transitional zone biopsy specimens. Using the Lower Anogenital Squamous Terminology criteria, p16 IHC results were classified as block staining, partial staining, or negative. Among 150 samples without morphologic evidence of AIN, p16 was negative in 85% and partial staining in 15%. AIN 1 (n=400) revealed diverse results: 28% negative, 35% partial, and 37% block staining. Among AIN 2 (n=298), 89% were block, 9% partial staining, and 2% negative. AIN 3 (n=152) revealed block (95%) or partial staining (5%). For the detection of AIN 2/3, p16 block staining yielded 91% sensitivity, 73% specificity, 80% positive predictive value, 91% negative predictive value, and a Youden Index of 0.64. Combining block staining and partial staining slightly increased sensitivity (99%) and negative predictive value (98%), but significantly decreased specificity (43%), positive predictive value (59%) and Youden Index (0.42, P<0.001). As with the cervix, p16 immunoreactivity correlates with morphologic diagnoses of AIN. Block staining offers the optimal diagnostic value for AIN 2/3. Caution is required since AIN 1 frequently exhibits block staining; the prognostic value of p16 warrants further investigation.